PUK6 RETROSPECTIVE PHARMACOECONOMIC STUDY OF THE USE OF CYCLOSPORINE A MICROEMULSION (SANDIMMUN® NEORAL®) IN COMPARISON WITH TACROLIMUS (PROGRAF®) FOR IMMUNOSUPPRESSION FOLLOWING KIDNEY TRANSPLANTATION  by Tolkushin, AG et al.
at-risk was set to 0.72, and it was assumed that new dialysis
modality distribution would reach by year 3. The model
allowed various sensitivity analyses. RESULTS: If PD utilization
increased to 25% without any reimbursement increase for PD,
5-year savings was estimated to be €13 million. If APD was
reimbursed by an additional €1300 per patient, 5-year savings
increased to €18 million, assuming overall PD utilization
increased to 30% and APD share of PD increased from 4.5% to
30%. If APD reimbursement increased an additional €2300 per
patient and APD share of PD increased to 50%, it would
require 35% of all PD patients undergoing dialysis treatment to
achieve €18 million savings. Finally, at this level of additional
APD reimbursement, 5-year savings increase to €25 million as
PD utilization increases to 40%. With €25 million in savings, an
additional 1478 patient-years of treatment could be provided in
Romania. CONCLUSION: With additional reimbursement for
PD and the resulting increase in PD utilization, there is an
opportunity for government to lower the total dialysis budget.
Government can apply the savings to treat additional ESRD
patients.
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OBJECTIVES: There is expected to be an increase in the number
of patients needing dialysis in the UK over the next 5 years.
Outcomes for the different modalities available, haemodialysis
(HD) and peritoneal dialysis (PD), have been shown to be similar
yet the majority of dialysis patients are treated with HD. Any
changes in dialysis delivery that could lead to a more efﬁcient use
of resources could increase the number of RRT patients that
could be treated. The objective of this evaluation is to project a
ﬁve-year impact on total dialysis costs when there is a hypoth-
esised shift in modality from HD to PD. METHODS: An Excel-
based budget impact model was used to estimate the impact of a
shift in modality utilisation. The model takes into account dialy-
sis modality shares, annual average cost of treating patients per
modality, annual RRT growth rate and years to reach new
modality distribution. Cost data from a recent UK study were
used. At baseline (June 2007) there were 23,133 RRT patients
undergoing dialysis therapy, 79% using HD and 21% using PD.
Annual direct cost per patient was £39,412 for HD, £20,764
for home HD (HHD), £22,350 for automated PD (APD), and
£16,355 for continuous ambulatory PD (CAPD). Total costs
included drug treatment and transport costs. At baseline, 2% of
the HD population was on HHD and 48% of the PD population
was on CAPD. RESULTS: If PD utilisation increases to 30% (of
which 60% is APD) by 2011, the cumulative 5-year budget is
reduced by a total of £166 million. This cumulative 5-year
savings can provide an additional 5,036 patient-years of treat-
ment. CONCLUSIONS: In the UK, an increased use of PD
provides an opportunity to treat additional patients within a
ﬁxed budget, which is a potential solution to the increased
demand for RRT in the coming years.
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OBJECTIVES: Identiﬁcation of the better drug for immunosup-
pression following renal transplantation. METHODS: Efﬁcacy
data sources included completed comparative randomized clini-
cal trials of Sandimmun Neoral and cyclosporine A generics
(Stolyarevich E. S. 2006, Taber D. J. et al. 2005, CTS 2001); costs
were derived from the wholesale prices of the study drugs
(Protek, Cia International, Shreya Corporation, as of 11 October
2006). The study evaluated the costs of initial and maintenance
immunosuppression, treatment of rejection episodes, and hemo-
dialysis necessitated by transplant death in the compared groups.
RESULTS: Analysis of randomized clinical trials has revealed
that Sandimmun Neoral is superior to cyclosporine A generics as
regards one-year renal graft survival rates (88% vs. 78%) (CTS
2001). Furthermore, application of cyclosporine A generics
entails more frequent episodes of acute rejection (25% vs. 39%),
recurrent rejection (4% vs. 13%), and rejection requiring admin-
istration of antibodies (8% vs. 19%, Taber D. J. et al. 2005). The
total cost of 2-year therapy was over 58.8 million roubles and 72
million roubles per 100 patients in the Sandimmun Neoral and
cyclosporine A generics groups, respectively. CONCLUSION:
Sandimmun Neoral is the leading alternative for immuno-
suppression following renal transplantation, i.e. it is preferable
from a clinicoeconomic perspective.
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OBJECTIVES: Identiﬁcation of the better drug for immunosup-
pression following renal transplantation. METHODS: Efﬁcacy
data sources included completed comparative randomized clini-
cal trials of cyclosporine microemulsion (Sandimmun Neoral,
CsA) and tacrolimus (Prograf, Tac). Costs were derived from the
wholesale prices of the study drugs (international drug distribu-
tor Shreya, as of 25 September 2006). Costs of other medicines
with the exception of calcineurin inhibitors (Mycophenolate
Mofetil, corticosteroids, Azathioprine), transplantation surgery,
diagnostic laboratory procedures, and pharmacokinetic monitor-
ing of blood concentrations of drugs were considered constant
and left out of calculations in this comparative study. RESULTS:
Analysis of randomized clinical trials has revealed similar efﬁca-
cies for both analyzed treatment options, whereas the safety
proﬁle of tacrolimus is more of a problem: the frequency rates of
the new onset post-transplant diabetes mellitus for CsA and Tac
are 26.5% and 33.6%, respectively, according to Vincenti F.
(2005), or 9.8% and 15.4%, respectively, as reported by Keown
P. (2004). The rates of diarrhea in the study of Levy G. (2005)
were 14% in the CsA group and 29% in those treated with Tac.
This study evaluated the costs of initial and maintenance immu-
nosuppression with Sandimmun Neoral and Prograf, which were
approximately 22,600 roubles vs. 58,700 roubles for initial
therapy and 176,300 roubles vs. 952,300 roubles for one-year
maintenance immunosuppression, respectively. The amount of
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money saved annually with the Sandimmun Neoral-based main-
tenance immunosuppression regimen was found to be about
776,000 roubles per transplant recipient per year. CONCLU-
SION: Sandimmun Neoral is the leading alternative for
immunosuppression following renal transplantation, i. e. it is
preferable from a clinicoeconomic perspective.
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OBJECTIVES: Standard medicinal care of patients with urge or
mixed urinary incontinence is muscarinic receptor antagonists.
Alternative forms of administration are available for these drugs.
The objective of this analysis was to compare the cost effective-
ness of the only available transdermal oxybutynin patch with
oral long-acting tolterodine tablets in the treatment of patients
with urge or mixed urinary incontinence in Sweden. METHODS:
The efﬁcacy of oxybutynin patches (3.9 mg/day), and tolterodine
tablets (4 mg/day) was compared in a 12 weeks randomized
clinical trial with 361 patients. The study demonstrated a com-
parable clinical efﬁcacy between the treatment alternatives in
number of daily incontinence episodes, average void volume and
QoL. A cost minimization analysis (CMA) was performed based
on this trial where direct medical costs related to drug treatments
and the costs of treating the major adverse events (AE)
(erythema, pruritus, rash, dry mouth, diarrhoea and constipa-
tion) were included. Resource utilization associated with the
treatment of the adverse events in Swedish clinical practice was
assessed by Swedish specialists in the ﬁeld. RESULTS: The CMA
shows that the total costs for 12 weeks tolterodine treatment is
1113.- SEK (~119.- €) per patient while the total costs for 12
weeks oxybutynin treatment is 1067.- SEK (~114.- €). The results
also demonstrate that the cost of treating AEs compose an insig-
niﬁcant fraction of the total treatment costs. This is due to the
low frequency of AEs requiring treatment, together with the low
costs for treating each AE. A number of sensitivity analyses
demonstrate the robustness of the results, including various sce-
narios for extrapolating the ﬁndings over 52 weeks. CONCLU-
SION: This CMA ﬁnds that oxybutynin patches (3.9 mg/day) is
a cost-effective treatment alternative to tolterodine tablets (4 mg/
day) for treating patients with urged or mixed urinary inconti-
nence in Sweden.
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OBJECTIVES: To assess clinical effectiveness and costs of MMF
or TAC use in immunosuppressive treatment from public payer’s
perspective in Poland. METHODS: Results of a SR of published
clinical trials conducted in December 2006 according to Polish
HTA Guidelines were used to assess effectiveness and safety for
immunosuppressive therapy schemes: TAC + AZA + GCS or
MMF + CsA + GCS. Weibull survival function was used to assess
the risk of acute kidney rejection, graftectomy, dialysis, retrans-
plantion (post-transplantation events) caused by used therapy.
Costs of treatment valid from public payer’s perspective were
taken into account. Pharmacotherapy, drug administration and
monitoring, patient monitoring, post-transplantation events
inﬂuenced the total treatment cost. Markov model was used to
assess costs of immunosuppressive therapies. Sensitivity analysis
was conducted according to range of costs of MMF or TAC
(+/-20%) available in Poland, MMF reimbursement categories
and discount rates for effects and costs in line with the Polish
HTA Guidelines (0% or 5%). All calculations were performed
for 2007 (1EUR = 3.8PLN). RESULTS: Indirect comparison
of immunosuppressive therapy schemes were taken into
account: TAC + AZA + GCS and MMF + CsA + GCS (CsA +
AZA + GCS as common comparator). Review of RCTs for these
therapies included in indirect comparison revealed no signiﬁcant
differences in their effectiveness and safety. TAC use was associ-
ated with signiﬁcantly higher costs from public payer’s perspec-
tive compared to MMF (difference: 97457PLN-135616PLN) per
therapy in accordance with assumed reimbursement category for
MMF (lump co-payment–50% co-payment). Sensitivity analysis
conﬁrmed that MMF’s scheme was cheaper compared to TAC’s
scheme from public payer’s perspective in Poland. CONCLU-
SION: MMF’s therapeutic scheme use in place of TAC’s scheme
lead to signiﬁcant savings for public payer in kidney transplant
immunosuppressive therapy in Poland.
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OBJECTIVES: The aim of our study was to assess the health
status and costs of patients with renal failure undergoing hae-
modialysis treatment in Hungary. METHODS: A questionnaire
survey was performed between November-December, year 2006
in the BBraun Dialysis Centre of Kistarcsa. All patients receiving
heamodialysis were invited to participate in the study. Demo-
graphic data, health care utilisation, informal care, transporta-
tion and other disease related expenses were surveyed. A generic
health status measure, the EQ-5D (range -0.6–1) was applied.
Mobility was measured by the Timed Up and Go Test
(normal < 20 sec). Costing was performed using human capital
approach method, productivity loss was based on average gross
wage (629Euro/month). RESULTS: Seventy-one patients (35
women, 36 men) were involved, mean age 62.3(15.0) years,
duration of haemodialysis was mean 3.9(4.2) years. 34 (47.8%)
patients were retired as many as on maintenance of disabled,
1-1-1 was on permanent sick-leave, unemployed or student.
Patients’ residence was mean 18.6(14.2) km from the dialysis
centre, 23(32.4%) had a car in their household, 2(2.8%) drived
on his own and 4(5.6%) were taken by a relative regularly,
57(80.3%) used the centres’ transportation network. 4(5.6%)
came by ambulance as much as travelled by bus or train.
9(12.7%) patients were living alone, 24(33.8%) with spouse,
37(52.1%) with other relatives, 1 in a nursing home, 28(39.4%)
received regular informal care mean 35.8(25.5) hours/week.
EQ-5D score was mean 0.635(0.3) and the score was signiﬁ-
cantly lower (p < 0.01) in all age-groups than in the Hungarian
population. The Up and Go Test was mean 19.89(17.09) sec.
Mean cost was 21 572 Euro/patient/year, direct medical costs
85.4%, direct non-medical costs 5.8%, indirect costs 8.8%.
CONCLUSION: Health status loss is signiﬁcant in chronic renal
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